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Glioblastoma multiforme (GBM) is the most common tumor of the CNS, and the
deadliest form of brain cancer. The rapid progression, the anatomic location in the
brain and a deficient knowledge of the pathophysiology, often limit the effectiveness
of therapeutic interventions. Current pillars of GBM therapies include surgical resection,
radiotherapy and chemotherapy, but the low survival rate and the short life expectation
following these treatments strongly underline the urgency to identify innovative and more
effective therapeutic tools. Frequently, patients subjected to a mono-target therapy, such
as Temozolomide (TMZ), develop drug resistance and undergo relapse, indicating that
targeting a single cellular node is not sufficient for eradication of this disease. In this
context, a multi-targeted therapeutic approach aimed at using compounds, alone or
in combination, capable of inhibiting more than one specific molecular target, offers
a promising alternative. Such strategies have already been well integrated into drug
discovery campaigns, including in the field of anticancer drugs. In this miniperspective,
we will discuss the recent progress in the treatment of GBM focusing on innovative and
effective preclinical strategies, which are based on a multi-targeted approach.
Keywords: glioblastoma, multitarget drug, multiple kinase inhibitor, small molecules, combination therapy
INTRODUCTION
Despite the recent advantages in the field of drug design, the development of innovative and
selective single-target drugs seems to be a task of little success, at least in the field of anticancer drug
research. Too often, therapies properly designed to act selectively against a single-target display a
low or no efficacy. Indeed, the cellular processes cannot be effectively modulated by a single-target
drug and this weakness can be attributed to the complexity of pathways and molecular alterations
implicated in the development and progression of cancer. The most tangible evidence of the failure
of one-drug-one-target therapy is observed in tumor forms that are particularly refractory and
resistant to chemotherapies, such as glioblastoma multiforme (GBM). GBM is the most common
tumor of the CNS and it is considered as the deadliest form of brain cancer with a survival rate
of less than 4% (Ohgaki and Kleihues, 2013). Moreover, the average survival rate in GBM patients
undergoing maximum safe surgical resection is approximately only 14 months. When surgery is
followed by adjuvant postoperative multimodal therapy, including both chemo- and radiotherapy
with conventional cytotoxic agents (Delgado-López and Corrales-García, 2016), the resulting life
expectation increases to about 5 years. Such a poor prognosis for GBM has been related to various
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factors, such as the rapid onset of the disease, cancer location,
and a deficient knowledge of the pathophysiology (Carlsson et al.,
2014), that limit the availability of efficient therapeutic tools, thus
highlighting the urgency to find novel efficacious treatments.
Among the great number of key signaling pathways involved
in GBM, the PI3K/Akt/mTOR pathway is one of the most
investigated and targeted, since it regulates several cellular
processes, including protein synthesis, proliferation, apoptosis,
angiogenesis, and migration (Li et al., 2016). EGFR, the upstream
activator of this pathway, is considered a common driver of GBM
progression, as it is mutated in 40% of all GBM cases (Hatanpaa
et al., 2010). EGFR substantially promotes the activation of
the downstream PI3-Kinase. This activation, however, also
occurs independently of EGFR, either through gain-of-function
mutations in PIK3CA or by a PTEN deregulation (McLendon
et al., 2008), which plays a pivotal role as signal suppressor in the
PI3K/Akt/PDK1 pathway. Similarly, protein p53, the guardian of
genome, is strongly associated with GBM. The p53 gene mutation
is linked to the transition from low-grade astrocytoma to high-
grade glioblastoma, since p53 mutant cells are able to overtake
normal p53 cells (Sidransky et al., 1992). The high frequency
of numerous mutations in GBM, as well as in many others
cancer types, suggest the existence of an intricate crosstalk link
between the diverse nodes, which regulate cancer development
and progression.
In addition, recent evidences suggest that several epigenetic
mechanisms are important factors that are contributing to
the pathogenesis of many different cancers, including GBM
(Lee et al., 2017). Given the critical role of gene expression,
several epigenetic modulators are being investigated as targets
for developing new drugs against GBM, either to be used alone
or in combination with other therapies (Lee et al., 2017; Chen
et al., 2018), and also to be exploited as novel prognostic and
predictive markers. In particular, histone deacetylase (HDAC)
inhibitors are emerging as a promising class of anticancer
drugs and are currently undergoing both preclinical and
clinical trials as innovative GBM therapeutic agents (Suraweera
et al., 2018). SGK1 (serum/glucocorticoid-regulated kinase 1) is
another important survival kinase that regulates cell proliferation
and differentiation (Kulkarni et al., 2018). Recent findings
showed that SGK1 is involved in modulating autophagy and
survival response to oxidative and reticulum stress, two factors
contributing to the development of resistance to radiotherapy.
Ortuso et al. identified a new SGK1 inhibitor, named SI113 that
showed to be particularly efficient against GBM in cellular models
both as a single agent and in combination with radiotherapy
(Talarico et al., 2015, 2016).
Noteworthy, in recent years the discovery of novel immune
strategies, especially checkpoint inhibitors, has paved the way on
new appealing treatments for several cancer settings. The mode
of action for checkpoint inhibitors is that they interfere with
the immune escape mechanisms that are adopted by tumor cells
to induce host immune system tolerance. Given that GBM is
particularly associated with severe immunosuppression, it might
be the ideal candidate for checkpoint inhibitor therapy (Huang
et al., 2017). Indeed, several clinical trials of checkpoint inhibitors
are ongoing in GBM, as well as in other brain carcinomas,
either as single agents or in combination with conventional
therapy (Buchbinder and Desai, 2016; Roth et al., 2016). Among
these, Nivolumab is an anti-programmed cell death-1 (PD-1)
monoclonal antibody that is currently undergoing the first
large randomized clinical trial (NCT 02017717) (Filley et al.,
2017). Even if these trials failed, the development of checkpoint
inhibitors remains a promising alternative strategy against GBM
that is currently being widely pursued.
Another important topic that is being widely investigated
is the key role played by cancer stem cells (GSCs), which
contribute to the high proliferative rate and to the infiltrative
nature of GBM (Huang et al., 2017). When compared to the
non-stem subpopulation, GSC subpopulation is innately resistant
to chemoradiotherapy as a whole (Chen et al., 2012; De Bacco
et al., 2016), and represents a prominent factor in GBM since
GSCs appear to be involved in tumor generation, therapeutic
resistance, and relapse (Bradshaw et al., 2016). As a matter of
fact, GSCs possess the ability for long-lasting self-renewal and
proliferation, thus giving birth to downstream progenitor cells
with reduced differentiation, mitotic, and a high self-renewal
potential, which, ultimately, lead to tumor growth (Bradshaw
et al., 2016). As a consequence of such features, GSCs are
becoming attractive targets to explore for the development of new
chemotherapies.
Current pillars of GBM therapies include surgical
resection and radiotherapy. Among chemotherapeutic agents,
Temozolomide (TMZ), which was first introduced in the late
1990s, still remains as the drug of choice in GBM treatment.
Recent research on TMZ has focused primarily on finding
innovative and improved delivery systems when the drug is
administered by itself (Khan et al., 2016, 2018; Lee, 2017) or in
combination with other therapies (Lam et al., 2018). In particular,
the combination with molecules that target HSP90 and HDAC
was found to enhance the therapeutic effect of TMZ when used
along with radiotherapy (Choi et al., 2014).
Today, several drugs are currently under investigation.
Ongoing clinical trials include agents targeting RTK and signal
transduction pathways, or antiangiogenic mechanisms through
different methods, such as gene therapy, immunotherapy,
reirradiation, radiolabeled drugs, and many others, alone or
in combination. Unfortunately, to date the results from these
trials have been quite disappointing. For instance, the first
generation of EGFR inhibitors, gefitinib and erlotinib, had raised
big expectations in GBM due to the success that they had
achieved in lung cancer treatment. However, even though the
alteration of EGFR is also found in brain cancer, these inhibitors
failed in GBM clinical trials (Rich et al., 2004). Similarly, the
experience with imatinib, an ATP binding site inhibitor of the
PDGFR, KIT, and ABL kinases, was disappointing (Mellinghoff
et al., 2011). Unsatisfactory results were also obtained with the
mTOR inhibitor Rapamycin, which was considered one of the
most advanced and promising agents in clinical development.
However, when Rapamycin was subjected to clinical trials
as single agent for PTEN deficient and recurrent GBM, the
outcome was quite poor (Mendiburu-Elicabe et al., 2012).
The overall disappointing results in studies performed with
patients affected by high grade glioma, has been associated
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to an Akt feedback mechanism that leads to the reactivation
of the entire PI3K pathway. Better results have come from
the combination of rapalogs and EGFR kinase inhibitors, even
though clinical trials for this therapeutic approach were also
complicated by the need to reduce the doses of the drugs in
order to attenuate toxicity (Kreisl et al., 2009; Reardon et al.,
2010).
Accordingly, monotherapy strategies are often inadequate to
achieve a powerful therapeutic intervention in GBM due to the
lack of efficacy and the onset of severe side effects. In general
the failure of the single agent approach may be caused by: (i)
the activation of feedback compensatory mechanisms, which
could lead to tumor cell resistance, and (ii) the deficiency of
reliable predictive biomarkers that could possibly be helpful in
selecting more sensitive patients for a given therapeutic approach
(Khan et al., 2013). Consistently, radio and chemotherapy are
widely used together in many solid cancers since they showed
to be particularly potent when used in combination (Brunner,
2016); highlighting the fact that concurrent inhibition of different
oncogenic proteins/networks could be a successful strategy for
treating this form of cancer. In this context, nowadays, multi-
targeted therapeutic strategies, by means of designing small
molecules able to inhibit more than one specific molecular target,
offer a promising alternative and have already been incorporated
in new therapeutic drug design approaches for the development
of anticancer drugs (Costantino and Barlocco, 2018; Ramsay
et al., 2018). Indeed, in the last few years, a considerable number
of compounds based on multitarget approach (MTA) have been
described (Petrelli and Valabrega, 2009; Chen et al., 2013; Jiang
et al., 2017).
In order to succeed in the development of multitarget agents,
the design strategy must focus first on the ability to distinguish
between healthy and cancer cells. To this aim, a ligand should
be designed with the ability to preferentially hit a gene/protein
network that is up-regulated in cancer cells, thus having a
lower impact on the healthy ones. In this context, a multimodal
agent capable of binding more than one specific target that
is differentially expressed should be more efficient in affecting
cancer cells, while having little effect on the cellular function of
healthy cells (Xie and Bourne, 2015).
The increasing need for effective therapies in GBM, prompted
us to focus this paper on examining another important approach
in this field that entails the development of poli-functional
preclinical strategies based on the use of small molecules, or
combination of more than one agent, capable of targeting
multiple nodes that are critical for GBM development and
progression.
THE MULTI-TARGETED STRATEGY
A multi-targeted strategy could be pursued through the co-
administration of drugs targeting different key nodes of
oncogenesis, or by merging different pharmacophores in a way to
create new molecular entities that are capable of simultaneously
and effectively hit different crucial nodes. However, one of the
limitations of multimodal inhibition comes from the potential
lack of selectivity against key targets of overexpressed networks
that could turn the multitarget ligand into a promiscuous agent
with a broad spectrum of activity, thus leading to the onset of
off-target effects (Giordano and Petrelli, 2008). Although, the
careful design of a ligand meant to specifically modulate several
targets chosen a priori should in part alleviate this problem, in
reality the dividing line between unwanted and desired effects
is extremely thin (Handler et al., 2018). As a consequence, in
order to overcome these drawbacks, the rational design of new
multitarget agents for cancer treatment is now differentiated
on the basis of the relationship between the crucial nodes
that are being targeted by the drugs. In the vertical inhibition
approach the molecular targets belong to the same cellular
signaling axis, while in the horizontal inhibition approach the
multitarget ligand interacts with different nodes of distinguished
pathways (Yap et al., 2013) (Figure 1). Both strategies commonly
attempt to block compensatory signaling mechanisms resulting
in improved clinical benefits. For instance, Pitter et al. (2011)
demonstrated that the vertical inhibition of Akt/mTOR pathway
by the use of perifosine (Akt inhibitor) and temsirolimus (mTOR
inhibitor) decreased tumor proliferation and induced apoptosis
both in vitro and in vivo models of GBM, thus suggesting that
the combination acts in synergy to inhibit the Akt/mTOR axis.
In regards of the horizontal strategy, the dual targeted inhibition
of MEK and PI3K pathway effectors promises to be a valid
strategy to overcome resistance to MEK inhibitor therapy in
metastatic colorectal cancer, which is characterized by a frequent
perturbation of the MAPK and PI3K signaling axis (Temraz
et al., 2015). Indeed, recent studies have shown that the dual
targeted inhibition of MEK and PI3K pathway effectors has an
enhanced efficacy against mutated colorectal cancer with respect
to treatment using a single agent.
Co-administration
Akt/mTOR and MDM2/mTOR Pathways
Many studies have shown that the Akt/mTOR pathway plays a
key role in the pathogenesis of cancer, including GBM (Gulati
et al., 2009; Jhanwar-Uniyal et al., 2015). GBM typically expresses
p53 with a wild-type amino acid sequence; the reactivation of p53
functionality in cancer cells can be achieved through the blockade
of the oncogenic inhibition caused by the AKT/mTOR pathway,
which in turn, triggers the undesired excessive stimulation of
MDM2. In this context, the simultaneous targeting of both
the AKT and p53 axes proved to be particularly effective in
cancer cells. A study performed in acute lymphoblastic leukemia
cell lines showed that the inhibition of the AKT pathway
synergizes with the MDM2 inhibitor Nutlin-3 to induce p53
reactivation and, consequently, cancer cells apoptosis (Zhu
et al., 2008). Analogously, the concomitant administration of the
mTOR inhibitor Everolimus and Nutlin-3 induces a synergistic
inhibition of GBM cells and GSCs viability (Daniele et al., 2015).
Preliminary studies also confirmed the presence of a synergic
antiproliferative activity in GBM cell lines after cotreatment
with the novel mTOR/AKT inhibitor FC85 and the MDM2/p53
blocker ISA27 (Daniele et al., 2015). The experimental data
showed that this combination reactivated the p53 pathway, which
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FIGURE 1 | Schematic representation of some multitarget strategies investigated to promote the block of compensatory signaling mechanisms in cancer.
was accompanied by a synergistic inhibition on U87MG cell
viability. The same effect has also been observed in U87MG
derived stem cells, thus resulting in improved apoptosis and a
significant promotion of stem cells differentiation. The antitumor
synergy elicited by the vertical inhibition of these two targets
was also observed in a preclinical animal model of liposarcomas
(Laroche et al., 2017). Results show a significant increase in
apoptosis induced by the combination of the two drugs with
respect to treatment using a single agent. Moreover, the co-
administration of the MDM2 antagonist RG7388 and the dual
inhibitor PI3K/mTOR BEZ235 was also able to significantly
reduce tumor growth rate, thus indicating that the combination
strategy designed to inhibit the AKT/mTOR signaling and to re-
activate p53 signaling at once, may be potentially effective in
different cancer types, including GBM.
PI3K/CDKs
In a paper published by Cheng et al. (2012), investigated the
possibility to simultaneously inhibit the lipid kinase PI3K and
the Cyclin-dependent kinases CDK1 and CDK2. PI3K is known
to block proliferation rather than induce apoptosis, and this
is probably one of the main reasons for the failure of using
PI3K inhibitors as monotherapy. Cheng et al decided to study
the effects induced by the combination of PI3K inhibition with
compounds able to target CDK1/2, which are also important
hallmarks in many cancers. PIK-75 (Hayakawa et al., 2007a,b),
initially discovered as a PI3Kα inhibitor, is also able to potently
induce apoptosis in glioma. The study performed by Cheng
showed that this compound has a multitarget (PI3K and
CDK1/2) profile. The blockade of CDK2 cooperates with the
inhibition of PI3K to drive apoptosis. Roscovitine is another
kinase inhibitor currently in trials for the treatment of solid
tumors, with a potent activity against CDK1 and CDK2 (Benson
et al., 2007; Hsieh et al., 2009). Results demonstrate that CDK1/2
inhibitors, siRNAs and roscovitine, in association with the
PI3K inhibitor PIK-90 drive the cells to programmed death
trough the blockade of the antiapoptotic protein Survivin.
Roscovitine given in combination with PIK-90 is well tolerated
in vivo and was found to induce apoptosis also in human
glioblastoma xenografts. In conclusion, the inhibition of PI3K,
CDK1, and CDK2 together can convert a cytostatic therapy due
to PI3K inhibition into an apoptotic one. These results offer
a preclinical rationale to evaluate this therapeutic strategy in
glioma patients.
Multitarget Ligands (MTDL)
PDK1/Aurora A
The Akt/PDK1 and AurA signaling pathways play a pivotal
role in GBM cellular survival/migration and in the self-renewal
of the GSCs. The dual inhibition of these targets represents
an innovative medicinal chemistry approach and few molecules
in literature showed the ability to hit both targets at once.
Our laboratory recently investigated the effect of the co-
administration of two selective inhibitors of PDK1 (MP7) and
AurA (Alisertib), compared to the treatment with a single
new multitarget inhibitor, namely SA16 (Sestito et al., 2016),
which proved to inhibit simultaneously both PDK1 and AurA
kinases, with IC50 values in the low nanomolar (416 and 35 nM,
respectively) (Daniele et al., 2017). Computational studies were
also performed to gain insights into the binding mode of SA16
against the PDK1 and AurA kinases. The results from these
studies suggest that SA16 binds to the DFG-out (i.e., allosteric)
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FIGURE 2 | Dual inhibitors’ chemical structures.
conformation of PDK1. This novel dual inhibitor showed the
ability to block cell proliferation, reduce tumor invasiveness, and
trigger cellular apoptosis in U87MG, ANGM-CSS, and U343MG
cell lines. Moreover, the new AurA/PDK1 dual-target molecule
SA16 showed significant efficacy against U87MG-derived stem
cells, inducing their differentiation and apoptosis. Taken together
these results show that the dual PDK1/AurA inhibition offers
an innovative and very promising multitarget strategy for GBM
therapy. In addition, the ability of this double kinase inhibitor to
also deplete GSC subpopulation, will further improve its efficacy
in the treatment of this severe disease.
PDK1/CHK1
In a study by Signore et al. (2014), the authors investigate the
effect induced by the staurosporine derivative UCN-01 in diverse
collection of GSC lines. Initially published as specific inhibitor of
PKC, UCN-01 was later discovered to have the ability to inhibit
multiple kinases: it is a potent inhibitor of CHK1 (Ki = 5.6 nM),
PDK1 (IC50 = 5.0 nM), PKCβ (IC50 = 10 nM), and CDKs (Ki:
CDK1 and CDC2 95 nM, CDK2 30 nM, and CDK4 3.6 mM), and
of other PKC isoforms that are inhibited with a lower potency.
UCN-01 activity was demonstrated both in vitro on glioma cell
lines and in vivo on U87MG xenografts (Davies et al., 2000; Zhao
et al., 2002; Komander et al., 2003; Gani and Engh, 2010). Signore
showed how the simultaneous multipathway inhibition by UCN-
01 significantly slows down the growth of GSCs in vitro. These
results were also confirmed in both orthotopic and heterotopic
GBM in vivo models. Additional investigations on the molecular
and functional effects of UCN-01 revealed that the sensitivity to
this agent is associated with the activation of PDK1 and CHK1.
The authors then suggest that a combined inhibition of PDK1,
which mediates survival signals, and CHK1, which initiates DNA
damage response, could be a potentially effective therapeutic
approach to target GCSs, thus reducing growth of human GBM
(Signore et al., 2014).
Akt/p70S6K
M2698 is an orally bioactive, potent, selective dual inhibitor of
p70S6K and Akt, currently in phase I clinical trials for patients
with advanced malignancies (ClinicalTrials.gov identifier:
NCT01971515) (Machl et al., 2016). M2698 demonstrated a
high potency both in vitro (IC50 = 1 nM for p70S6K, Akt1, and
Akt3 inhibition; IC50 = 17 nM for pGSK3β indirect inhibition)
and in vivo (IC50 = 15 nM for pS6 indirect inhibition). M2698
also revealed a fairly selective activity, since only six out of 264
kinases had an IC50 within 10-fold of p70S6K. Both in vitro and
in vivo investigations indicate that M2698 effectively induces a
dose-dependent inhibition of p70S6K substrate phosphorylation,
which provides a potent PI3K/Akt/mTOR pathway blockade.
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Moreover, it simultaneously targets Akt, thus overcoming the
compensatory feedback loop. M2698 demonstrated the ability
to cross the BBB, reduce tumor growth and extend survival in
an orthotopically implanted model of (human) U251 GBM.
Recent studies prove that this compound is also able to inhibit
tumor growth in mouse breast xenograft models derived from
PI3K/Akt/mTOR pathway-dysregulated cell lines (MDA-MB-453
and JIMT-1) (Machl et al., 2016).
EGFR/PKC
Acridine yellow G is a yellow staining agent emitting a
strong bluish-violet fluorescence that belongs to the acridine
family of chemical compounds characterized by a nitrogen
tricyclic scaffold. Acridine-based compounds have shown a
wide variety of therapeutic properties, including antibacterial,
antimalarial, and antitumoral. Among the acridine tricycle
heteroatomic compounds, acridine yellow G (3,6-diamino-2 7-
dimethylacridine, Figure 2) showed to be the most promising
of the series for anti-GBM therapy. When tested in U87MG
cell lines, acridine yellow G directly inhibits the kinases EGFR
and PKCs with IC50 values of ∼7.5 and 5 µM, respectively,
consequentially blocking the mTOR signaling and triggering the
cell cycle arrest in the G1 phase, and, in turn, activating the
apoptotic process in tumors. In particular, acridine yellow G
preferentially blocks cell proliferation of the most malignant
U87MG/EGFRvIII cells (PTEN-deficient U87MG glioblastoma
cells that overexpress EGFRvIII) over the less malignant PTEN
stably transfected U87MG cells (Qi et al., 2012). In vivo studies
indicated that Acridine yellow G has the ability to induce a
reduction of the tumor volumes in both subcutaneous and
intracranial mice models. Toxic effects in animals subjected to
chronic treatment were undetectable. Globally, results indicate
that Acridine yellow G is a safe and effective therapeutic agent
for the treatment of aggressive gliomas, as well as other types of
human cancers, such as lung cancer, that are also inhibited by this
compound (Qi et al., 2012).
CONCLUSION
Over the years, the pathophysiological properties of GBM
have been extensively studied in order to find new potential
targets useful for developing innovative and successful therapies.
However, despite the progress made in our understanding of
the disease and the development of new therapies, the patient’s
prognosis still remains poor. Many therapeutic strategies adopted
in the last decades, led to the development of various new agents
capable of hitting nodes that are crucial for the survival of
GBM. Among new treatments, those based on monotherapy have
generally failed to meet the initial expectations, raising the notion
that a strategy capable of targeting multiple kinases should be
more effective in attacking this disease.
It is also important to note that intrinsic or acquired
resistance continues to be one of the main obstacles to
overcome in both single and multitarget approaches. Indeed,
many factors are involved in the mechanism of resistance in
GBM, including: (i) an increase in the migration of cancer cells,
angiogenesis, and proliferation, (ii) a reduction in the sensitivity
to apoptosis resulting from the expression of antiapoptotic
regulatory proteins, and (iii) an increase in both drug eﬄux
expression and molecular proliferation pathways, such as Akt
and NF-kB signaling (Garner et al., 2013). In particular, for a
single agent treatment, drug-resistance is mainly caused by the
activation of compensatory mechanisms, or the acquisition of
genomic and/or epigenomic changes. On this basis, it seems
logical that a multitarget approach using the right mechanism-
based combination of different targeted therapies might be
the able to delay, or even overcome, drug resistance. Further
pre-clinical and clinical investigations are needed to verify
whether these multimodal approaches represent a valid strategy
to ultimately circumvent drug resistance (Groenendijk and
Bernards, 2014).
In conclusion, the simultaneous inhibition of different cellular
pathways involved in cancer development is emerging as the
new promising strategy to achieve clinically meaningful tumor
regression and to limit the ability of cancer cells to develop escape
mechanisms, which would lead to the onset of chemoresistance.
Among these strategies being pursued are those that involve:
(i) a combination of multiple selective inhibitors directed on
the same pathway, but different targets, (ii) the simultaneous
blockade of different key proteins of the cross-talked signaling
pathways, or (iii) a multidirectional inhibition on different
oncoproteins throughout distinct pharmacological approaches
(e.g., combining lipid and cyclin-dependent kinases). All of
these strategies could represent a valid approach in GBM
therapy, especially when targeted to the genetic pattern of the
patient.
Finally, we also need to highlight the very promising concept
of synthesizing single molecular entities suitably designed to hit
multiple targets at once and with an adequate ADMET profile.
When compared to the co-administration of multiple drugs,
single multitarget molecules could present several advantages,
including a lower risk of drug–drug interaction, an improved
bioavailability, a reduced susceptibility to adaptive resistance and
a better pharmacokinetic profile.
Our goal in writing this paper was to explore the main
trends in preclinical investigation, with a special focus on
those therapeutic approaches that simultaneously target multiple
oncoproteins at once, as these have shown the best potential of
being successful against GBM.
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